Founder and Chief Executive Officer
Prior to founding Viscient, Mr. Murphy co-founded Organovo, the world's premier 3D bioprinting company of which he is the former CEO and Chairman Emeritus, in 2007, and led all company operations until 2017. He co-invented the NovoGen MMX bioprinter platform (named one of TIME magazine’s “Best inventions of 2010”) and grew Organovo through early investments and corporate partnerships, including major alliances with Astellas and Merck. Organovo received a number of accolades including being named one of the Most Innovative companies of the year in 2012 by MIT Technology Review and 2015 by Fast Company, and Most Audacious companies in 2013 by Inc. Magazine. Organovo went public and commenced trading on the NYSE in 2013 and NASDAQ in 2016. Organovo has since focused on the development of three-dimensional liver, kidney, and cancer tissues. The most advanced program, liver tissue, has grown to encompass a range of applications from commercial use for pharmaceutical toxicology prediction to the preclinical development of human 3D liver patches for transplant patients. Prior to co-founding Organovo, Mr. Murphy spent ten years at Amgen in roles of increasing responsibility, including four years as the Global Operations Leader of denosumab, now marketed as Prolia & Xgeva ($3B+ annual sales). He holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management. Mr. Murphy serves on the Board of the California Life Sciences Association and Adgero Biopharmaceuticals.
Prior to founding Viscient, Dr. Miner held research leadership positions at Ardea Biosciences, a member of the Astrazeneca group, and Ligand Pharmaceuticals. His responsibilities at Ardea covered the Biology program as it relates to discovery, preclinical, translational and clinical development. He was Head of Molecular and Cellular Biology at Ligand Pharmaceuticals. He is a Faculty Advisor and Molecular Biology Institute Associate at San Diego State University and is a Scientific Advisory Board Member for ARTA Bioscience. His Ph.D. graduate work was conducted in Virology at Oregon State University with a post-doctoral fellowship at the University of California San Francisco in glucocorticoid gene regulation. He has drug discovery experience in the Inflammation, Oncology, Endocrine and Cardiovascular drug discovery therapeutic areas and his work has led to or enhanced the development of multiple marketed compounds. His target areas of expertise include Nuclear Receptors, Kinases and Transporters. He has published over 60 peer reviewed articles and book chapters and is an inventor on multiple patents.
Jeffrey N. Miner
Founder and Chief Scientific Officer